Inosine monophosphate dehydrogenase (IMPDH) is an important target for immunosuppressive, antiviral and anticancer therapy. This enzyme catalyzes the key reaction in guanine nucleotide biosynthesis: the conversion of IMP into XMP with the concomitant reduction of NAD. The reaction involves a dehydrogenase step that produces NADH and a covalent E-XMP* intermediate and a hydrolysis step where E-XMP* is converted to XMF'. We have solved the structure of the mizoribine monophosphate complex of IMPDH that resembles the transition state for the hydrolysis of E-XMP*. This structure reveals that LMPDH undergoes a large conformational change after NADH departs, transforming the enzyme into a hydrolase. This conformational change positions a mobile flap in the NADH site, with a conserved Arg-Tyr dyad adjacent to E-XMP*. Surprisingly, the Arg-Tyr dyad appears to act as the general base that activates water. The flap competes with drugs such as mycophenolic acid, so that the conformational change also appears to be a major determinant of drug selectivity.
INTRODUCTION
Inosine monophosphate dehydrogenase catalyzes the pivotal step in guanine nucleotide biosynthesis: the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) with concomitant reduction of NAD.
IMPDH controls the guanine nucleotide pool, which in turn controls proliferation and many other important cellular processes. IMPDH inhibitors are antiproliferative and are used as immunosuppressive (mycophenolic acid and mizoribine), antiviral (ribavirin) and anticancer (tiazofurin) chemotherapy (1). IMPDH inhibitors may also be useful antimicrobial agents, although compounds with the appropriate selectivity have not yet been developed.
The IMPDH reaction involves two very different chemical transformations: hydride transfer and hydrolysis ( Fig. 1) ( 2 ) . Substrates bind randomly to form E-IMP-NAD. The active site Cys attacks IMP and a hydride is transferred to NAD, forming the E-XMP* intermediate. NADH must dissociate prior to hydrolysis of E-XMP*; hydrolysis of E-XMP* is at least partially rate-limiting in all of the IMPDHs examined to date. Surprisingly, MZP, the active metabolite of the immunosuppressive drug mizoribine, behaves like a transition state analog for the hydrolysis reaction although its structure does not resemble the transition state (3). All hydrolases have some mechanism to activate water, but this mechanism has proven difficult to identify in IMPDH. 1 The IMPDH reaction and structures of inhibitors.
A. Mechanism of IMP dehydrogenase
Mycophenolic acid (MPA) is a potent inhibitor of human IMPDH but a poor inhibitor of microbial enzymes such Tritrichomonus foetus IMPDH. Understanding the mechanistic basis of this selectivity could provide important insights into designing microbial selective IMPDH inhibitors. MPA traps E-XMP* by binding in the nicotinamide half of the NADH site. Interestingly, MPAresistant IMPDHs have higher values of k,,, than MPAsensitive enzymes. This observation suggests that there is an underlying mechanistic link between drug selectivity and catalysis.
We have discovered that MPA selectivity is determined in part by residues at the MPA site, and in part by a conformational change (43). The MPA site of T. foetus IMPDH contains two residues that are different in the human enzyme: Lys310 and Glu43 1. When these residues are replaced with their human counterparts, the resulting mutant is 20-fold more sensitive to MPA than wild-type, but 20-fold less sensitive than human IMPDH (4). This result demonstrates that drug selectivity is determined by residues outside the MPA binding site. While the IMP site is highly conserved, the adenosine half of the NADH site varies dramatically among IMPDHs and thus could be the missing determinant of drug selectivity. The nicotinamide and adenosine subsites are independent in the human enzyme. In contrast, the adenosine subsite is coupled to the nicotinamide subsite in the T. foetus enzyme, which indicates that a conformational change propagates across the NAD site in the parasite IMPDH but not in the human enzyme (5). The energy required to induce this conformational change is more than enough to account for the missing MPA affinity of the double mutant.
Here we identify the conformational change that controls drug selectivity. This conformational change occurs in mid catalytic stream, converting the enzyme from a dehydrogenase to a hydrolase.
RESULTS AND DISCUSION
We first proposed that the conformational change involved a mobile flap that is disordered in the human E-XMP**MPA complex (6), but generally believed to close over the adenosine site. We demonstrated that mutations in this flap increase MPA affinity although these residues do not contact MPA. However, the conformational change did not involve simple closing of the flap over the active site as expected (7) .
The structure of the E-MZP complex of T. foetus IMPDH solved the mystery of the conformational change (8) . This structure is the first of an IMPDH complex with this important immunosuppressive agent. Remarkably, the mobile flap is completely ordered and occupies the NADH site. The flap docks into the adenosine subsite with a conserved Arg-Tyr dyad protruding into the nicotinamide subsite (Fig 2) . Thus the flap competes with MPA for the nicotinamide site.
This structure also explains the surprising transition state analogy of MZP as well as the mystery of water activation. The active site Cys319, MZP and a water molecule are arranged in a tetrahedral geometry resembling the transition state (Fig. 2) . Modeling a purine ring over the base of MZP, the water is poised to attack C2, with Cys319 on the other side of the purine ring as would be expected of the leaving group. The water appears to be activated by the conserved Arg418-Tyr419 dyad. Thus the closed conformation of the flap is the underlying mechanistic link that controls both hydrolysis and drug selectivity.
Mutagenesis experiments confirm that Arg418 and Tyr419 are required for the hydrolysis of E-XMP*, but not for the reduction of NAD. Mutations of the conserved ArgTyr dyad selectively disrupt the hydrolysis step. In Arg418Ala, the value of ka, is decreased -5OOx, but the rates of hydride transfer and NADH release are comparable to wild-type. Similarly, in Tyr419Phe, the value of bat decreases lox, but again hydride transfer and NADH release are comparable to wild-type. These observations indicate that the conserved Arg-Tyr dyad activates water. More surprisingly, the mutagenesis experiments suggest that Arg418 is acting as the catalytic base. We make this statement with caution because the high pKa of Arg in solution would seem to preclude such a role.
These experiments indicate that the flap closes into the active site after NADH dissociates from E-XMP*. converting the enzyme into a hydrolase. We believe the equilibrium between the open and closed conformations of E-XMP* controls MPA selectivity. The higher the affinity of the flap for the NADH site, the weaker MPA will bind. The more the closed conformation is favored. the faster E-XMP* will be hydrolyzed and, since the hydrolysis of E-XMP* is rate-limiting, the higher the value of k,,,. 'I'his explains why MPA resistant IMPDHs also have higher values of k,,,, and accounts for the properties of T.foetus IMPDH. Conversely, the lower the affinity of the flap for the NADH site, the higher the affinity of MPA and the lower the value of k,,,. These are the properties of human IMPDH.
Fig. 2. The transition state analogy of MZP.
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